Interested in holding a Walk/Run event? Click here for information.
- Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in MPS VII
- Synageva BioPharma announces active Investigational New Drug application for SBC-103 for the treatment of MPS IIIB
- ArmaGen announces FDA acceptance of IND application for AGT-182 for the treatment of MPS II
- FDA grants orphan drug designation for BMN 250 for the treatment of MPS IIIB